Can Pfizer's Stock Break This Disappointing Streak?

Pfizer's stock recently rallied, achieving a ~3% year-to-date gain, following a White House deal that provides a three-year tariff exemption, voluntary Medicaid drug price reductions, and a $70 billion U.S. investment commitment, temporarily alleviating investor concerns after years of underperformance. Despite this positive catalyst, the company faces significant future revenue challenges from diminishing COVID sales and impending patent cliffs, projected to cost $16-18 billion by 2030. However, CEO Albert Bourla aims to generate $25 billion in new revenue through strategic acquisitions, like Seagen, and R&D, presenting a potentially undervalued long-term opportunity given its current P/E of less than 13 and PEG ratio around 1, despite ongoing uncertainties.

Analysis

Pfizer (PFE 1.03%) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare. It has developed many medicines over the years; most recently, it has been known for developing its highly successful COVID vaccine Comirnaty. Growth and innovation have enabled the company to become a household name and a leader in healthcare. Investors, however, have been having doubts about the business and its ability to grow in the future. In the past three years, the stock has produced negative returns. Since 2022, It has lost more than half its value. Can the stock break its downward streak, and finish this year in positive territory? A recent deal with the White House gives investors hope For a while, it looked like Pfizer's stock was destined for another year in the red. The U.S. government has been targeting pharma companies with tariffs this year, and tougher vaccine policies have also been weighing on the company's valuation. But on Sept. 30, Pfizer reached a deal with President Donald Trump that will give it a grace period of three years before tariffs would be applied to its imported pharmaceutical products. The company is voluntarily lowering the price of drugs for Medicaid and will sell some drugs on TrumpRx, a new government-run direct-to-consumer website for pharmaceuticals. In addition, the company also pledged to invest $70 billion on research and manufacturing in the U.S. over the coming years. This appeared to alleviate at least some concerns for investors because shares of Pfizer jumped on the recent news. On Oct. 1, it closed above $27 for the first time since January. The stock is now in positive territory for 2025, with year-to-date gains around 3%. It's not a huge return, but it is an indication that investors are feeling a bit more bullish about the healthcare stock again and that it might be able to finish the year in the green. Pfizer still faces a lot of questions Although the stock has been rallying recently, it's not out of the woods by any means. COVID sales are diminishing for Pfizer, and the company is facing patent cliffs on multiple key drugs. CEO Albert Bourla has previously said the company could stand to lose between $16 billion and $18 billion in revenue between 2025 and 2030 as it loses patent protection on some of its drugs. However, he's also planning to add $25 billion in new revenue by the end of the decade through acquisitions and research and development. NYSE: PFE Key Data Points Its acquisition of oncology company Seagen could generate up to $10 billion in sales by 2030 alone. It was also expecting that its mRNA vaccine portfolio might bring in a similar amount, but that is questionable now that the U.S. government appears to be rethinking vaccine recommendations. The business may end up looking a whole lot different over the next five-plus years. While its fundamentals still look good (it generated nearly $11 billion in profits over the trailing 12 months), investors are hesitant about whether or not they can trust this struggling stock, especially amid such uncertain times in the healthcare sector. Why Pfizer may be worth taking a chance on There's definitely risk with investing in Pfizer as it's taking on multiple acquisitions and facing patent cliffs, and there are plenty of question marks around its vaccine sales. However, with a beaten-down valuation, a price-to-earnings multiple of less than 13, and a price-to-earnings-growth ratio right around 1 (based on analyst projections), it's a low-priced stock that comes with a good margin of safety. Pfizer has been working on expanding its pipeline and giving itself more opportunities to grow in the long run. Although not all of its efforts might pay off, even if some do, there could be plenty of catalysts in the future to send the stock higher. Whether it breaks its streak of declines this year is irrelevant because investing in a quality company at a cheap price could ensure your investment ends up in the green over the long haul, and that's why Pfizer looks like a solid buy, regardless of what happens in the short term. Pfizer's stock has demonstrated a significant reversal, turning positive year-to-date for 2025 with a 3% gain after a prolonged period of underperformance that saw its value halve since 2022. This rally was directly catalyzed by a deal with the White House, which provides a three-year grace period from tariffs on imported pharmaceuticals in exchange for voluntary price reductions for Medicaid and a commitment to invest $70 billion in U.S. operations. The news pushed the stock above $27 for the first time since January, signaling a shift in investor sentiment. Despite this positive development, the company faces substantial long-term headwinds. Management projects a revenue loss between $16 billion and $18 billion from 2025 to 2030 due to key patent expirations, compounded by diminishing COVID-19 product sales. To counteract this, CEO Albert Bourla has outlined a strategy to add $25 billion in new revenue by 2030, heavily reliant on acquisitions like the oncology firm Seagen, which is projected to contribute up to $10 billion in sales. The company's current valuation appears modest, with a price-to-earnings multiple below 13 and a price-to-earnings-growth ratio near 1, reflecting the market's uncertainty about this strategic pivot despite the company generating nearly $11 billion in profit over the trailing twelve months.

Key Decisions for Investors

• Given the low valuation metrics, including a P/E ratio under 13 and a PEG ratio around 1, value-focused investors may view the current share price as an attractive entry point, betting on the success of the long-term growth strategy.
• Investors should closely monitor the execution of Pfizer's revenue replacement plan, specifically the integration and performance of the Seagen acquisition and pipeline developments, as these are critical to offsetting the projected $16-18 billion revenue gap from upcoming patent cliffs.
• The recent stock appreciation is heavily linked to a temporary, three-year tariff reprieve, so portfolios should be positioned to account for the significant regulatory and political risk that remains a factor in the U.S. pharmaceutical market.